Q1 2023 Non-GAAP Operating Income

Impression After 120 Days as CEO M Strong commercial portfolio AUSTEDO®, AJOVY®, UZEDYTM and upcoming biosimilars Promising innovative pipeline Strong innovative pipeline with proven targets / MoAs Solid core businesses Strong generation of cash to pay down debt Taking proactive measures to address short-term challenges around COGS management Laz Strong historical capabilities "Can do" culture with an innovative mindset Reaffirming 2023 Non-GAAP Outlook teva |4|

View entire presentation